Comprehensive Analysis of DMRT3 as a Potential Biomarker Associated with the Immune Infiltration in a Pan-Cancer Analysis and Validation in Lung Adenocarcinoma

Abstract

Doublesex and Mab-3 related Transcription Factor 3 (DMRT3) is associated with the prognosis of some tumors. It is possible to explore the role of DMRT3 in the cancer process using bioinformatic approaches and experimental validation. We comprehensively explored the clinical and immunological characteristics of DMRT3. The DMRT3 expression is abnormal in human cancers and correlates with clinical staging. A high DMRT3 expression is significantly associated with poor overall survival (OS) in KIRC, KIRP, LUAD, and UCEC. Amplification was the greatest frequency of the DMRT3 alterations in pan-cancer. The OS was significantly lower in the DMRT3 altered group than in the DMRT3 unaltered group (P = 0.0276). The DMRT3 expression was significantly associated with MSI in three cancer types and TMB in six cancer types. The DMRT3 expression was significantly correlated with the level of the immune cell infiltration and the immune checkpoint genes. The DMRT3 was involved in some pathways in pan-cancer. DMRT3 may play a role in chemotherapy and may be associated with chemoresistance. A ceRNA network of KCNQ1OT1/miR-335-5p/DMRT3 was constructed in LUAD. DMRT3 was significantly upregulated in the LUAD cell lines. DMRT3 was aberrantly expressed in pan-cancer and may promote tumorigenesis and progression via different mechanisms. DMRT3 can be used as a therapeutic target to treat cancer in humans.

Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer

“…The molecule was TLX2 [ENSG00000115297]. We processed UCSC XENA ( https://xenabrowser.net/datapages/ , accessed on 10 June 2022) into RNAseq data in TPM format for TCGA ( https://portal.gdc.cancer.gov , accessed on 10 June 2022) and GTEx by Toil process 14 – 18 . We log-transformed the RNAseq data for comparative analysis.…”

Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma

“…Pan cancer analysis is employed to enhance the comprehension of the fundamentally disrupted molecules in pan cancer, thereby facilitating the identification of biomarkers for timely cancer detection and targeted therapeutic interventions [ 11 ]. TCGA contained multi-omics data for 33 tumors, allowing exploration of genetic alterations in different cancer types [ 11 ].…”

“…The resulting data were visualized using the ggplot2 package [ 14 ]. The subgroups encompassed a diverse range of 33 tumor types [ 11 , 15 ].…”

“…The RNAactDrug database ( http://bio-bigdata.hrbmu.edu.cn/RNAactDrug/index.jsp ) was employed to conduct an analysis on the association between ZNF692 expression and drug sensitivity across various types of cancer [ 11 ].…”

“…In order to investigate the potential regulatory network of ZNF692 in HCC, we employed miRTarBase ( http://mirtarbase.cuhk.edu.cn/ ) and TarBase V.8 ( https://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=tarbasev8%2Findex ) databases to predict the miRNAs that interact with ZNF692 [ 11 ]. Subsequently, utilizing the miRNAs identified from the screening process, we utilized StarBase ( http://starbase.sysu.edu.cn/ ) and LncBase Predicted v.2 ( https://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=lncbasev2/index-predicted ) databases to predict the lncRNAs that bind to these miRNAs.…”